A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This is a study to characterize the pharmacokinetics as well as safety and tolerability of a
single oral dose of LCZ696 200 mg in subjects with mild and moderate hepatic impairment
compared to matched healthy subjects
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination